{"id":46778,"date":"2024-09-13T17:53:00","date_gmt":"2024-09-13T17:53:00","guid":{"rendered":"http:\/\/ee5a1d603d58119a8426a2bc18edca4a"},"modified":"2024-11-03T15:11:47","modified_gmt":"2024-11-03T15:11:47","slug":"from-practice-changing-data-to-future-innovation-patient-outcomes-to-doctors-wellbeing-the-esmo-congress-2024-takes-a-holistic-view-of-oncology","status":"publish","type":"post","link":"https:\/\/ogkologos.com\/en\/from-practice-changing-data-to-future-innovation-patient-outcomes-to-doctors-wellbeing-the-esmo-congress-2024-takes-a-holistic-view-of-oncology\/","title":{"rendered":"From Practice-Changing Data to Future Innovation, Patient Outcomes to Doctors\u2019 Wellbeing, the ESMO Congress 2024 Takes a Holistic View of Oncology"},"content":{"rendered":"<ul>\n<li>Studies presented at the ESMO Congress 2024 bring immunotherapy into new disease areas with high unmet need<\/li>\n<li>Novel agents and technologies show promise in various indications and offer a glimpse into the future of oncology<\/li>\n<li>Efforts continue to raise awareness and reduce burnout in the oncology workforce<\/li>\n<\/ul>\n<p>Barcelona, Spain&nbsp;\u2013 The ESMO Congress 2024 taking place 13-17 September in Barcelona, Spain, offers a comprehensive view of the current drug development landscape, with existing medicines demonstrating benefit in additional applications and new agents emerging in large numbers as the range of potential molecular targets for therapy continues to expand. At the opening press conference of ESMO\u2019s flagship annual event, wide-sweeping progress made with novel immunotherapy combinations was highlighted alongside results that prefigure how cancer diagnosis and treatment could be transformed in the future.&nbsp;<\/p>\n<h3>Immunotherapy gains further ground<\/h3>\n<p>ESMO 2024 Scientific Chair Dr Rebecca Dent underlined the importance of the overall survival data to be presented from the KEYNOTE-522 study in this difficult-to-treat breast cancer subtype, as the therapy is not yet approved everywhere in the world. Dent similarly highlighted that for bladder cancer, where treatment options were limited in the past, the positive phase III NIAGARA trial marks another milestone in a recent surge of research advances already <a href=\"https:\/\/dailyreporter.esmo.org\/esmo-congress-2023\/genitourinary-cancers\/combination-therapies-with-immunotherapy-and-adcs-prolong-overall-survival-in-urothelial-carcinoma\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"external-link\">reported<\/a> at the ESMO Congress 2023.<\/p>\n<p>In anal cancer, a disease usually diagnosed in the advanced stages and where rates of relapse on standard treatment with chemoradiotherapy are high, a combination of immunotherapy and chemo is opening up new, much-needed possibilities for patients. (1) As ESMO President Dr Andr\u00e9s Cervantes explained: \u201cPOD1UM-303\/InterAACT 2 is the first phase III randomised controlled trial not just of immunotherapy, but overall in this tumour type. Though uncommon in the developed world, anal cancer is more prevalent in low and middle-income countries and, alongside HPV vaccination as an effective means of prevention, this is an important step in treating a disease that is currently still managed with medicines developed 50 years ago.\u201d<\/p>\n<p>Important data will also be presented on the long-term outcomes of the first melanoma patients treated with immunotherapy, providing novel insights into its survival benefits and toxicities. (2) (3) \u201cThe arrival of immune checkpoint inhibitors and combination therapies dramatically changed the situation for melanoma patients, who previously had few treatment options and poor life expectancy. Talking about 10-year survival outcomes is outstanding in and of itself, but as clinicians we also need to understand what happens to these patients over time to be able to better differentiate whom to give which treatment to based on the expected benefits,\u201d Dent explained.<\/p>\n<h3>An expanding landscape of therapeutic agents<\/h3>\n<p>With several phase III trials reporting positive results, patients with metastatic castration-resistant prostate cancer will benefit from new options to treat this fatal condition going forward. \u201cProstate cancer is very common, so it is exciting to see research producing a multitude of therapies to help patients beyond castration resistance, including a novel combination of the androgen receptor antagonist enzalutamide with radium 223 (4), combination immunotherapy, (5) and several new compounds (6),\u201d said Dent.<\/p>\n<p>Research introducing antibody-drug conjugates (ADCs) is equally prolific, with over 100 agents currently under development and data to be presented at the ESMO Congress 2024 covering the entire spectrum of phase I, (7) (8) phase II (9) and phase III\/IV trials (10) (11). \u201cADCs are a smart way of delivering chemotherapy as the antibodies it is bound to in a complex molecular structure deliver their payload directly inside the tumour cells they recognise, preserving healthy tissue and thus offering reduced toxicity alongside potentially higher antitumour activity,\u201d said Cervantes.<\/p>\n<h3>An eye on the future of oncology<\/h3>\n<p>While many research results presented over the next five days will change clinical practice in the short term, the ESMO Congress 2024 will also provide a perspective on the directions in which oncology will evolve in the future during a dedicated <a href=\"https:\/\/cslide.ctimeetingtech.com\/esmo2024\/attendee\/confcal\/show\/session\/240\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"external-link\">Presidential Symposium<\/a>. Cervantes highlighted artificial intelligence for its potential to be applied to medical images not just from radiology devices, but also from pathology slides (12), to capture information that the human eye cannot and eventually facilitate better diagnosis, treatment and follow-up.<\/p>\n<p>The ESMO President took the opportunity to announce the launch of a new ESMO AI and Digital Oncology Congress in 2025. \u201cESMO has a responsibility to keep doctors updated on what is happening in these areas, which are going to transform the way we receive information about cancer and the way we make decisions in oncology,\u201d he said, explaining the rationale for the new event.<\/p>\n<h3>Preventing burnout among the oncology workforce<\/h3>\n<p>The ESMO Congress 2024 is also an important occasion on which to address current issues affecting the profession. Among these, ensuring the resilience and wellbeing of the cancer workforce in the face of increasing pressures from staff shortages and rising workloads will be the subject of a dedicated <a href=\"https:\/\/cslide.ctimeetingtech.com\/esmo2024\/attendee\/confcal\/show\/session\/205\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"external-link\">session<\/a>. A vital message in this regard was conveyed in the recently published <a href=\"https:\/\/www.esmo.org\/newsroom\/press-and-media-hub\/esmo-media-releases\/esmo-calls-for-concerted-action-to-prevent-burnout-and-foster-well-being-within-the-oncology-workforce\" class>ESMO Resilience Task Force recommendations to manage psychosocial risks, optimise well-being, and reduce burnout in oncology<\/a>, a proposal for multi-tiered, concerted action to support and retain oncologists in the field.<\/p>\n<p>\u201cBurnout is a situation in which a professional feels overwhelmed by their responsibilities and is no longer able to cope with the difficulties of performing their day-to-day activities, with possible knock-on effects on the individual\u2019s mental health, such as anxiety, depression or insomnia,\u201d said Cervantes. \u201cWe cannot afford to lose our workforce, so we must raise awareness and tackle burnout as the common problem that it has become.\u201d An additional, qualitative analysis (13) of the findings from the surveys on how oncologists can best be helped and supported in their mission to care for cancer patients will also be presented in Barcelona.&nbsp;<\/p>\n<p>ESMO 2024 Press Officer Dr Angela Lamarca highlighted the holistic nature of the ESMO Congress in several respects: \u201cWe will see everything from the earliest preclinical data to phase III trials comparing new treatment regimens with our current practice, a multitude of different agents and technologies under development, emerging knowledge across a broad range of disease types beyond the most common cancers\u2014and discussions around the health and wellbeing of not just patients, but also oncology professionals,\u201d she said.<\/p>\n<p>With a wealth of high-quality data selected from over 5,000 submitted abstracts, and 600 experts onsite to present and discuss the latest research results with 33,000 registered attendees, the ESMO Congress 2024 is starting as a record-breaking edition. \u201cThese unprecedented figures illustrate the strength and the global reach of this meeting in delivering new science to the oncology community,\u201d Cervantes concluded.<\/p>\n<h3>Notes to Editors&nbsp;<\/h3>\n<p>Please make sure to use the official name of the meeting in your reports: <strong>ESMO Congress 2024<\/strong>&nbsp;<\/p>\n<p>Official Congress Hashtag: <strong>#ESMO24.<\/strong> Follow it to stay up to date and use it to take part in the conversation on <a href=\"https:\/\/x.com\/myESMO\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"external-link\">X (Twitter)<\/a>, <a href=\"https:\/\/www.linkedin.com\/company\/european-society-for-medical-oncology\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"external-link\">LinkedIn<\/a>, <a href=\"https:\/\/www.instagram.com\/esmo_eur_oncology\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"external-link\">Instagram<\/a>, <a href=\"https:\/\/www.facebook.com\/esmo.org\/\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"external-link\">Facebook<\/a>&nbsp;<\/p>\n<h3>Disclaimer<\/h3>\n<p>This press release contains information provided by the author of the highlighted abstract and reflects the content of this abstract. It does not necessarily reflect the views or opinions of ESMO who cannot be held responsible for the accuracy of the data. Commentators quoted in the press release are required to comply with the ESMO Declaration of Interests policy and the ESMO Code of Conduct.<\/p>\n<div class=\"qaToggle\">\n<p>References<\/p>\n<div class=\"qaToggle-answer collapse\" id=\"question-idm45954969816416\">\n<ol>\n<li>LBA2 \u2018POD1UM-303\/InterAACT 2: Phase III study of retifanlimab with carboplatin-paclitaxel (c-p) in patients (Pts) with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) not previously treated with systemic chemotherapy (Chemo)\u2019 will be presented by Sheela Rao during Presidential Symposium I, Saturday 14 September, 16:52 &#8211; 17:04 CEST in Barcelona Auditorium &#8211; Hall 2<\/li>\n<li>LBA43 \u201810-y survival outcomes from the phase 3 CheckMate 067 trial of nivolumab plus ipilimumab in advanced melanoma\u2019 will be presented by James Larkin during the Mini Oral session \u2018Melanoma and other skin tumours\u2019, Sunday 15 September, 14:45 &#8211; 14:50 CEST in Oviedo Auditorium &#8211; Hall 3<\/li>\n<li>LBA44 \u2018Pembrolizumab vs Ipilimumab in Advanced Melanoma: 10-Year Follow-Up of the Phase 3 KEYNOTE-006 Study\u2019 will be presented by Caroline Robert during the Mini Oral session \u2018Melanoma and other skin tumours\u2019, Sunday 15 September, 14:50 &#8211; 14:55 CEST in Oviedo Auditorium &#8211; Hall 3<\/li>\n<li>LBA1 \u2018A randomized multicenter open-label phase III trial comparing enzalutamide vs. a combination of RA223 and enzalutamide in asymptomatic or mildly symptomatic patients with castration-resistant prostate cancer and bone metastases. First results of EORTC-1333\/PEACE III\u2019 will be presented by Silke Gillessen during Presidential Symposium I, Saturday 14 September, 16:30 &#8211; 16:42 CEST in Barcelona Auditorium -Hall 2<\/li>\n<li>LBA67 \u2018Cabozantinib plus atezolizumab versus second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer (MCRPC): final overall survival results of the phase 3, randomized, open-label contact-02 study\u2019 will be presented by Neeraj Agarwal during the Proffered Paper session \u2018GU tumours, prostate\u2019, Sunday 15 September, 15:30 &#8211; 15:40 CEST in Valencia Auditorium &#8211; Hall 5<\/li>\n<li>LBA65 \u2018Efficacy of 177Lu-PNT2002 in PSMA-positive mCRPC following progression on an androgen-receptor pathway inhibitor (ARPI) (SPLASH)\u2019 will be presented by Oliver Sartor during the Proffered Paper session \u2018GU tumours, prostate\u2019, Sunday 15 September, 14:45 \u2013 14:55 CEST in Valencia Auditorium &#8211; Hall 5<\/li>\n<li>Abstract 610O \u2018Preliminary results from a Phase 1, first-in-human study of DS-9606a, a Claudin 6 (CLDN6)-directed antibody\u2013drug conjugate (ADC), in patients (pts) with tumor types known to express CLDN6\u2019 will be presented by Manish R. Patel during the Proffered Paper session 2 \u2018Developmental therapeutics\u2019, Sunday 15 September, 15:35 &#8211; 15:45 CEST in Salamanca Auditorium &#8211; Hall 5<\/li>\n<li>Abstract 721MO \u2018Phase I, Two-Part, Multicenter First-In-Human (FIH) Study of TORL-1-23, A Novel Claudin 6 (CLDN6) Targeting Antibody Drug Conjugate (ADC) In Patient With Advanced Solid Tumors\u2019 will be presented by Gottfried E. Konecny during the Mini Oral session 2 \u2018Gynaecological cancers\u2019, Sunday 15 September, 15:50 &#8211; 15:55 CEST in Santander Auditorium &#8211; Hall 5<\/li>\n<li>Abstract 849O \u2018Phase II study of trastuzumab deruxtecan in patients with HER2-positive recurrent\/metastatic salivary gland cancer: results from the MYTHOS trial\u2019 will be presented by Ichiro Kinoshita during the Proffered Paper session \u2018Head and neck cancer\u2019, Sunday 15 September, 11:00 &#8211; 11:10 CEST in Valencia Auditorium &#8211; Hall 5<\/li>\n<li>Abstract 1816O \u2018A multicentre, randomized, double-blind, placebo-controlled study of olanzapine-based triplet antiemetic therapy for prevention of delayed and persistent nausea and vomiting induced by trastuzumab deruxtecan in patients with metastatic breast cancer: ERICA study (WJOG14320B)\u2019 will be presented by Hitomi Sakai during the Proffered Paper session \u2018Supportive and palliative care\u2019, Saturday 14 September, 15:32 &#8211; 15:42 CEST in Pamplona Auditorium &#8211; Hall 3<\/li>\n<li>LBA18 \u2018Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ advanced\/metastatic breast cancer (mBC) with or without brain metastases (BM): DESTINYBreast-12 primary results\u2019 will be presented by Nancy Lin during the Proffered Paper session \u2018Breast cancer, metastatic\u2019, Friday 13 September, 16:00 &#8211; 16:10 CEST in Barcelona Auditorium &#8211; Hall 2<\/li>\n<li>Abstract 1942O \u2018Application of GigaPath, an open-weight billion-parameter AI foundation model based on a novel vision transformer architecture for cancer mutation prediction and TME analysis\u2019 will be presented by Carlo Bifulco during Presidential Symposium III, Monday 16 September, 16:42 &#8211; 16:54 CEST in Barcelona Auditorium &#8211; Hall 213 K. H. J. Lim, K. Kamposioras, E. \u00c9lez, J. B. A. G. Haanen, C. Hardy, K. Murali, M. O\u2019Connor, C.<\/li>\n<li>Oing, K. Punie, E. de Azambuja, J. Y. Blay and S. Banerjee on behalf of the ESMO Resilience Task Force, 2024. ESMO Resilience Task Force recommendations to manage psychosocial risks, optimise well-being, and reduce burnout in oncology. <a href=\"https:\/\/www.esmoopen.com\/article\/S2059-7029(24)01403-0\/fulltext\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"external-link\">https:\/\/doi.org\/10.1016\/j.esmoop.2024.103634<\/a>\n<\/li>\n<li>Abstract 709O \u2018Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: overall survival results from the randomized, double-blind, phase 3 ENGOT-CX11\/GOG-3047\/KEYNOTE-A18 STUDY\u2019 will be presented by Domenica Lorusso during Presidential Symposium I, Saturday 14 September, 17:14 &#8211; 17:26 CEST in Barcelona Auditorium &#8211; Hall 2<\/li>\n<li>LBA4 \u2018Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Overall survival results from the phase 3 KEYNOTE-522 study\u2019 will be presented by Peter Schmid during Presidential Symposium II, Sunday 15 September, 16:30 &#8211; 16:32 CEST in Barcelona Auditorium &#8211; Hall 2<\/li>\n<li>LBA5 \u2018A randomized phase 3 trial of neoadjuvant durvalumab plus chemotherapy followed by radical cystectomy and adjuvant durvalumab in muscle-invasive bladder cancer (NIAGARA)\u2019 will be presented by Thomas B. Powles during Presidential Symposium II, Sunday 15 September, 17:14 &#8211; 17:26 CEST in Barcelona Auditorium &#8211; Hall 2<\/li>\n<li>Abstract 1960O \u2018Identification of bladder cancer patients that could benefit from early post-cystectomy immunotherapy based on serial circulating tumour DNA (ctDNA) testing: preliminary results from the TOMBOLA trial\u2019 will be presented by Jorgen Bjerggaard Jensen during Proffered Paper session 2 \u2018GU, non-prostate\u2019, Monday 16 September, 08:40 &#8211; 08:50 CEST in Sevilla Auditorium &#8211; Hall 2<\/li>\n<li>Abstract 440O \u2018First in human study of the mRNA-based cancer vaccine CVGBM in patients (pts) with newly diagnosed and surgically resected MGMT-unmethylated glioblastoma (GBM): first results from the dose escalation phase\u2019 will be presented by Ghazaleh Tabatabai during the CNS Tumours Proffered Paper session, Friday 13 September, 14:00 &#8211; 14:10 CEST in Pamplona Auditorium &#8211; Hall 3<\/li>\n<li>Abstract 441O \u2018A phase I clinical trial on the intracranial administration of autologous CD1c(BDCA-1)+ \/CD141(BDCA-3)+ myeloid dendritic cells (myDC) in combination with ipilimumab (IPI) and nivolumab (NIVO) in patients with recurrent high-grade glioma (rHGG)\u2019 will be presented by Bart Neyns during the CNS Tumours Proffered Paper session, Friday 13 September, 14:10 &#8211; 14:20 CEST in Pamplona Auditorium &#8211; Hall 3<\/li>\n<li>Abstract 442O \u2018A phase I clinical trial of intrathecal injection of allogeneic CAR-\u03b3\u03b4T cells targeting B7H3 for the treatment of patients with recurrent glioblastoma\u2019 will be presented by Yulun Huang during the Proffered Paper session \u2018CNS tumours\u2019, Friday 13 September, 14:20 &#8211; 14:30 CEST in Pamplona Auditorium &#8211; Hall 3<\/li>\n<\/ol><\/div>\n<\/div>\n<p><a href=\"https:\/\/www.esmo.org\/newsroom\/press-and-media-hub\/esmo-media-releases\/from-practice-changing-data-to-future-innovation-patient-outcomes-to-doctors-wellbeing-the-esmo-congress-2024-takes-a-holistic-view-of-oncology\">Source<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Studies presented at the ESMO Congress 2024 bring immunotherapy into new disease areas with high unmet need Novel agents and technologies show promise in various indications and offer a glimpse into the future of oncology Efforts continue to raise awareness and reduce burnout in the oncology workforce Barcelona, Spain&nbsp;\u2013 The ESMO Congress 2024 taking place [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[5137],"tags":[],"class_list":["post-46778","post","type-post","status-publish","format-standard","hentry","category-world-news"],"_links":{"self":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts\/46778","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/comments?post=46778"}],"version-history":[{"count":1,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts\/46778\/revisions"}],"predecessor-version":[{"id":46909,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts\/46778\/revisions\/46909"}],"wp:attachment":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/media?parent=46778"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/categories?post=46778"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/tags?post=46778"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}